

**FORM-39A**  
**(THE DRUGS & COSMETICS ACT 1940 & RULES THEREUNDER)**

<b>Sample Name</b>	METOCLOPRAMIDE HCL INJECTION-IP.5.0mg./ml	<b>Mfg Lic No</b>	[REDACTED]	
<b>Submitted By</b>	Quality Control Advisor. (MMDSL) Shillong.	<b>Report No</b>	[REDACTED]	
<b>Address</b>	DHS LaitumkhrahNHM, EastKhasi Hills Meghalaya.	<b>Receipt Date</b>	19-Mar-24	
<b>Mfg By</b>	N.S.	<b>Report Date</b>	05-Apr-24	
<b>Supplied By</b>	N.S.	<b>Ref No</b>	N.S.	
<b>Batch No</b>	<b>Mfg. Date</b>	<b>Exp Date</b>	<b>Batch Size</b>	<b>Sample Qty</b>
MMDSL/QC-0100	12/2023	11/2025	N.S.	30 AMPOULES.

**RESULT OF ANALYSIS**

Date / Period of Performance of test 19/03/2024 to 05/04/2024.

Reference to protocol :- I.P-2022.

Description :- Clear colourless solution filled in amber colour glass ampoules.

Identification A (by U.V) :- Complies.  
B & C :- Complies.

		Limit	
		Lower	Upper
pH	:- 4.21	3.0	5.0
Bacterial endotoxin	:- Less than NMT 2.5EU/mg of Metoclopramide		NMT 2.5EU/mg of Metoclopramide

Related substances (by HPLC) :- Complies.

Nominal volume :- 2ml.

Extractable volume :- 2.04ml NLT 2ml.

Sterility :- Complies with the test for sterility.

Particulate matter :- Complies.

Assay (by U.V) :- Each ml contains:-

			Limit		
	Obtained	Claim	Lower	Upper	Method
Content of Metoclopramide hydrochloride eq. to Anhydrous Metoclopramide hydrochloride:-	4.98mg	5.0mg	4.5mg	5.5mg	IP.

NOTE:- SAMPLE CONSUMED IN [REDACTED]

Report: In Opinion of the undersigned, The sample ref [REDACTED] as defined in the Act and the rules made there under per IP.

- NOTE :**
1. The result listed refer only to the tested samples and applicable parameter. Endorsement of products is neither inferred nor implied.
  2. Sample not drawn by us. Total liability of this laboratory limited to the invoice amount.
  3. This report is not be reproduced wholly or in part and cannot be used as an evidence in the Court of Law and should not be used in any advertising media without special permission in writing.